RxSight, Inc. reported a strong start to 2024, with first-quarter revenue increasing by 69% to $29.5 million compared to the previous year. The growth was driven by increased sales of Light Adjustable Lenses (LAL) and Light Delivery Devices (LDD). The company's net loss decreased to $(9.1) million, and adjusted net loss also improved. RxSight increased its full-year revenue, gross margin and operating expense guidance.
First quarter revenue increased by 69% to $29.5 million compared to Q1 2023.
LAL sales increased by 92% year-over-year, driven by the sale of 20,218 lenses.
LDD sales increased by 18% year-over-year, with an installed base of 732 devices.
Net loss improved to $(9.1) million, or $(0.25) per share, compared to $(13.2) million, or $(0.42) per share in Q1 2023.
RxSight increased its 2024 full-year revenue, gross margin and operating expense guidance.
Analyze how earnings announcements historically affect stock price performance